TG THERAPEUTICS, INC. Selling, General and Administrative Expense
TG THERAPEUTICS, INC. (TGTX) reported Selling, General and Administrative Expense of $82.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- TG THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $82.13M, a 47.76% increase year-over-year.
- TG THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $88.22M, a 75.27% increase year-over-year.
- TG THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $62.74M, a 61.04% increase year-over-year.
- TG THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $63.37M, a 51.01% increase year-over-year.
- TG THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2025 was $232.03M, a 50.38% increase from fiscal 2024.
- TG THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2024 was $154.30M, a 25.75% increase from fiscal 2023.
- TG THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2023 was $122.71M, a 28.51% increase from fiscal 2022.
- TG THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2022 was $95.48M, a 25.46% decline from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $82.13M 10-Q · filed 2026-08-05 | $170.35M 10-Q · filed 2026-08-05 | $233.09M derived: sum of 3 quarters · filed 2026-08-05 | $296.46M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $88.22M 10-Q · filed 2026-05-06 | $150.96M derived: sum of 2 quarters · filed 2026-05-06 | $214.34M derived: sum of 3 quarters · filed 2026-05-06 | $269.92M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $62.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $126.12M derived: sum of 2 quarters · filed 2026-02-27 | $181.70M derived: sum of 3 quarters · filed 2026-08-05 | $232.03M 10-K · filed 2026-02-27 | |
| 2025-09-30 | $63.37M 10-Q · filed 2025-11-05 | $118.96M derived: sum of 2 quarters · filed 2026-08-05 | $169.29M 10-Q · filed 2025-11-05 | $208.25M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $55.59M 10-Q · filed 2026-08-05 | $105.92M 10-Q · filed 2026-08-05 | $144.88M derived: sum of 3 quarters · filed 2026-08-05 | $186.84M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $50.33M 10-Q · filed 2026-05-06 | $89.29M derived: sum of 2 quarters · filed 2026-05-06 | $131.26M derived: sum of 3 quarters · filed 2026-05-06 | $170.05M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $38.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $80.93M derived: sum of 2 quarters · filed 2026-02-27 | $119.72M derived: sum of 3 quarters · filed 2026-02-27 | $154.30M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $41.97M 10-Q · filed 2025-11-05 | $80.76M derived: sum of 2 quarters · filed 2025-11-05 | $115.33M 10-Q · filed 2025-11-05 | $146.49M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-06-30 | $38.79M 10-Q · filed 2025-08-08 | $73.37M 10-Q · filed 2025-08-08 | $104.52M derived: sum of 3 quarters · filed 2026-02-27 | $137.29M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-03-31 | $34.58M 10-Q · filed 2025-05-09 | $65.73M derived: sum of 2 quarters · filed 2026-02-27 | $98.50M derived: sum of 3 quarters · filed 2026-02-27 | $129.22M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2023-12-31 | $31.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $63.92M derived: sum of 2 quarters · filed 2026-02-27 | $94.64M derived: sum of 3 quarters · filed 2026-02-27 | $122.71M 10-K · filed 2026-02-27 | |
| 2023-09-30 | $32.77M 10-Q · filed 2024-11-07 | $63.48M derived: sum of 2 quarters · filed 2024-11-07 | $91.55M 10-Q · filed 2024-11-07 | $139.53M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | $30.71M 10-Q · filed 2024-08-09 | $58.78M 10-Q · filed 2024-08-09 | $106.76M derived: sum of 3 quarters · filed 2025-03-03 | $121.02M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | $28.07M 10-Q · filed 2024-05-06 | $76.05M derived: sum of 2 quarters · filed 2025-03-03 | $90.30M derived: sum of 3 quarters · filed 2025-03-03 | $102.94M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2022-12-31 | $47.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $62.23M derived: sum of 2 quarters · filed 2025-03-03 | $74.87M derived: sum of 3 quarters · filed 2025-03-03 | $95.48M 10-K · filed 2025-03-03 | $70.01M 10-K · filed 2023-03-01 |
| 2022-09-30 | $14.25M 10-Q · filed 2023-11-06 | $26.89M derived: sum of 2 quarters · filed 2023-11-06 | $47.50M 10-Q · filed 2023-11-06 | $79.91M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | $12.64M 10-Q · filed 2023-08-04 | $33.25M 10-Q · filed 2023-08-04 | $65.66M derived: sum of 3 quarters · filed 2024-02-29 | $100.56M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-03-31 | $20.61M 10-Q · filed 2023-05-08 | $53.02M derived: sum of 2 quarters · filed 2024-02-29 | $87.92M derived: sum of 3 quarters · filed 2024-02-29 | $121.94M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | $32.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $67.31M derived: sum of 2 quarters · filed 2024-02-29 | $101.33M derived: sum of 3 quarters · filed 2024-02-29 | $128.09M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $34.90M 10-Q · filed 2022-11-09 | $68.92M derived: sum of 2 quarters · filed 2022-11-09 | $95.68M 10-Q · filed 2022-11-09 | $139.54M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | $34.02M 10-Q · filed 2022-08-09 | $60.78M 10-Q · filed 2022-08-09 | $104.64M derived: sum of 3 quarters · filed 2023-03-01 | $139.93M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $26.76M 10-Q · filed 2022-05-10 | $70.62M derived: sum of 2 quarters · filed 2023-03-01 | $105.92M derived: sum of 3 quarters · filed 2023-03-01 | $120.35M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | $43.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $79.16M derived: sum of 2 quarters · filed 2023-03-01 | $93.59M derived: sum of 3 quarters · filed 2023-03-01 | $107.85M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $35.30M 10-Q · filed 2021-11-08 | $49.73M derived: sum of 2 quarters · filed 2021-11-08 | $63.99M 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $14.43M 10-Q · filed 2021-08-06 | $28.70M 10-Q · filed 2021-08-06 | |||
| 2020-03-31 | $14.26M 10-Q · filed 2021-05-10 | ||||
| 2019-12-31 | $15.03M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |